{"id":470616,"date":"2024-01-04T09:42:47","date_gmt":"2024-01-04T14:42:47","guid":{"rendered":"https:\/\/platohealth.ai\/x%e2%80%91chem-transitions-executives-into-new-roles-appoints-new-chief-executive-officer-medical-device-news-magazine\/"},"modified":"2024-01-05T05:11:33","modified_gmt":"2024-01-05T10:11:33","slug":"x%e2%80%91chem-transitions-executives-into-new-roles-appoints-new-chief-executive-officer-medical-device-news-magazine","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/x%e2%80%91chem-transitions-executives-into-new-roles-appoints-new-chief-executive-officer-medical-device-news-magazine\/","title":{"rendered":"X\u2011Chem Transitions Executives Into New Roles, Appoints New Chief Executive Officer – Medical Device News Magazine","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n
\n

X-Chem<\/h2>\n

X-Chem the leading provider of innovative solutions in early-stage drug discovery, today announced executive management team changes aimed at expanding its position as a premium provider of integrated services to drug hunters.<\/p>\n

Karen Lackey<\/h2>\n

Karen Lackey, currently Chief Scientific Officer, will transition to the role of Chief Executive Officer. Karen\u2019s extensive drug discovery experience in both pharma and service organizations makes her the ideal leader to guide X-Chem into the next phase of its evolution. Under Karen\u2019s leadership, X-Chem will continue innovating in data-accelerated drug discovery utilizing a unique combination of computational science and experimental data generation to catalyze a small molecule drug discovery revolution.<\/p>\n

Matthew Clark<\/h2>\n

Current X-Chem<\/a> Chief Executive Officer Matthew Clark will transition to the role of President and Chief Scientific Officer. In this role, Matt will focus on maintaining X-Chem\u2019s edge in novel drug discovery technologies, ensuring X-Chem\u2019s clients access a full range of innovative services to advance their pipelines. A drug discovery technology thought leader, Matt will continue to have a crucial role aligning X-Chem\u2019s scientific capabilities to its corporate mission and clients\u2019 needs.<\/p>\n

\u201cI\u2019m very proud of what the team<\/a> has accomplished over the past four years, transitioning X-Chem from a boutique DNA-encoded library (DEL) shop to a global, integrated service provider,\u201d said newly appointed X-Chem President and CSO Matt Clark. \u201cNow, under Karen\u2019s visionary leadership, I am incredibly excited to participate in the next stage of our journey. X-Chem has the potential to transform the way small molecule drugs are discovered.\u201d<\/p>\n

\u201cI am so excited about the future of small molecule drug discovery and X-Chem\u2019s role in that future,\u201d said incoming CEO Karen Lackey. \u201cIn my first six months at X-Chem, I have seen top-tier science and met many amazingly talented scientists. Together, we can continue to bring incredible innovation to drug discovery, unlocking the biological problems of the future to the benefit of patients.\u201d<\/p>\n<\/div>\n